1	Identifying the target population for primary Respiratory Syncytial Virus two-step
2	prevention in infants:
3	Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN)
4	
5	Marine Jourdain ¹ , Mehdi Benchaib ² , Dominique Ploin ^{3,4} , Yves Gillet ³ , Etienne Javouhey ³ ,
6	Côme Horvat ³ , Mona Massoud ⁴ , Marine Butin ⁵ , Olivier Claris ⁵ , Bruno Lina ^{1,4} , on behalf of
7	the VRS study group in Lyon, Jean-Sebastien Casalegno ^{1,4}
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	 1 Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Centre de Biologie Nord, Institut des Agents Infectieux, Laboratoire de Virologie, Lyon, France; 2 Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de Médecine et de la Reproduction, Bron, France, 3 Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de Réanimation Pédiatrique et d'Accueil des Urgences, Bron, France, 4 CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, F-69007, Lyon, FR. 5 Hospices Civils de Lyon, Service de Gynécologie-Obstétrique, Hôpital Femme-Mère-Enfant, Bron, France ; 6 Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de Néonatologie et de Réanimation Néonatale, Bron, France
20	Keywords: RSV: Bronchiolitis: Predictive Score: Lower Respiratory Tract Infection Primary
28	prevention, monoclonal antibody, public health, vaccines
29	Corresponding author: Jean-Sebastien CASALEGNO
30	CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm,
31	U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon; 7 rue
32	Guillaume Paradin, 69 372 Lyon Cedex 08
33	tel: +33478778621 mail: jean-sebastien.casalegno@chu-lyon.fr
34	

35 **Summary**

36 Background:

Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection related
hospitalisations in infants (RSVh). Most of these infants are younger than 6 months old with
no known risk factors. An efficient RSVh prevention program should address both mothers
and infants, relying on Non-Pharmaceutical (NPI) and Pharmaceutical Interventions (PI). This
study aimed at identifying the target population for these two interventions.
Methods:
Laboratory-confirmed RSV-infected infants hospitalised during the first 6 months of life were

enrolled from the *Hospices Civils de Lyon* birth cohort (2014 to 2018). Clinical variables
related to pregnancy and birth (sex, month of birth, birth weight, gestational age, parity) were
used for descriptive epidemiology, multivariate logistic regression, and predictive score
development.

48 **Findings**:

49 Overall, 616 cases of RSVh in 45 648 infants were identified. Being born before the epidemic 50 season, prematurity, and multiparity were independent predictors of RSVh. Infants born in 51 January or June to August with prematurity and multiparity, and those born in September or 52 December with only one other risk factor (prematurity or multiparity) were identified as 53 moderate-risk, identifying the mothers as candidates for a first level NPI prevention program. 54 Infants born in September or December with prematurity and multiparity, and those born in 55 October or November were identified as high-risk, identifying the mothers and infants as 56 candidates for a second level (NPI and PI) intervention.

57 Interpretation:

It is possible to determine predictors of RSVh at birth, allowing to enrol early the target
population in a two-level RSV prevention intervention.

60 Funding

61 None.

62 **Research in context**

63 Evidence before this study

In infants, the global burden of disease caused by the respiratory syncytial virus (RSV) is increasingly recognised. Nowadays the prevention programs are limited to the only licensed drug, Palivizumab, a humanised monoclonal antibody that shows some benefit in preventing RSV in high-risk infants. With the recent encouraging progress obtained using a maternal vaccine candidate and long half-life monoclonal antibodies administered to newborns, as well as the impact of Covid-19 non-pharmaceutical interventions on the RSV epidemic, there is an urgent need to revisit this prevention paradigm from a much broader perspective.

71 Added value of this study

Using a hospital birth cohort (NOHAN strategy) split into a training and a testing dataset, we were able to determine strong maternal and newborn predictors for the risk of RSV hospitalisation. Month of birth, multiparity, and prematurity were sufficient to accurately identify low-, moderate-, and high-risk groups in the validating cohort.

76 Implications of all the available evidence

Using the NOHAN strategy, future parents could be enrolled early during pregnancy followup in a health-related behaviour change program and then be proposed a vaccine boost for the pregnant women or neutralizing monoclonal antibodies for the newborns. The thresholds for triggering each intervention can be adjusted to the local epidemiology, the resources available, and the evolving evidence concerning the cost-efficiency of the future interventions. Stakeholders, healthcare professionals and policy makers must acknowledge this opportunity when designing the future of RSV prevention programs.

Introduction 85

91

86 Respiratory syncytial virus (RSV) infection is the predominant cause of lower respiratory tract infection (LRTI) in infants.^{1,2} In developed countries, RSV represents the leading cause 87 of hospitalisation during the first year of life,³ with up to 3% of all infants hospitalised every 88 year.⁴ Severe cases are more frequent in infants younger than 3 months⁵ and in infants with 89 known risk factors such as prematurity, lung or heart diseases, and immunodeficiency.⁶ 90 However, most infants hospitalised with RSV LRTI have no known risk factors.^{2,7,8}

92 Although RSV is now recognised as a major health burden worldwide, preventive approaches 93 remain limited. Non-Pharmaceutical Interventions (NPI) such as hand hygiene, breastfeeding, 94 and avoiding exposure to smoke or persons with acute respiratory illness are effective in reducing the risk of infection with respiratory viruses in infants.^{9,10} The implementation of 95 96 NPI on a large scale during the COVID-19 pandemic, which strongly reduced the RSV epidemic,¹¹ advocates for a stronger implementation of NPI. Pharmaceutical Intervention (PI) 97 98 is currently limited to the only licensed drug, Palivizumab, a humanised monoclonal antibody 99 that shows some benefit in preventing RSV in high risk infants.¹² More recently, encouraging 100 progress was made using a fusion protein nanoparticle vaccine administered to pregnant women¹³ and long half-life monoclonal antibodies administered to newborns.¹⁴ Considering 101 102 the numerous PIs for RSV prevention currently being evaluated in clinical trials, there is a 103 reasonable hope that in coming years, PI will be broadly recommended to the general 104 population.¹⁵

105 Nevertheless, successful implementation of the future prevention programs largely relies on 106 their capacity to target the mothers of infants with the higher risk. Recently, it has been 107 reported that prophylaxis regimens, adjusted for regional variations in terms of RSV 108 seasonality, may improve protection compared to the implementation of nationally recommended regimens.^{15,16} 109

5/24

Predictive models can help adjust the preventive action to the target population.¹⁷ Regarding the risk of RSV-associated hospitalisation (RSVh), most of the published predictive models have focused on high risk preterm infants.^{18–22} Only Houben *et al* proposed a simple prediction rule that can identify infants at risk of RSV LRTI, but the cohort was limited in size and the score designed only for clinical use.²³ The Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN) strategy proposed herein aimed to adjust multi-level mother-infant interventions according to the risk

117 of RSVh at the general population level. The cut-off values can be adapted to balance the

118 resources available and the effectiveness of the preventive approach.

119

120 Methods

121 Data sources

122 Demographic and laboratory data were collected retrospectively. First, the administrative 123 registry of all infants born in the University Hospitals of Lyon (Hospices Civils de Lyon, 124 HCL) was used. Stillborn children or those living outside the region were excluded. This 125 database includes the following variables of interest: gender (male/female), month of birth, 126 gestational age (WG), maternal parity (primiparity/multiparity), plurality (single/multiple 127 gestation), childbirth type (vaginal birth/caesarean section), birth weight, and geographical 128 living area (postcode). Patients with at least one missing data for any studied variable were 129 excluded. The virology laboratory database was then used to identify, among all infants born 130 in the HCL and hospitalised during the RSV season with acute respiratory infection 131 symptoms, those with a respiratory sample positive for RSV.²⁴

Cases were defined as a new admission, during the first 6 months of life, to one of the conventional paediatric hospital departments of the HCL with an RSV positive sample during hospital stay. This 6-month follow-up period is in line with the preventive approaches proposed herein (NPI, maternal vaccination program, monoclonal antibodies administered at

birth) which are mostly protective over the first 6 months of life.¹⁷ Presumed nosocomial
cases (i.e. cases observed during the birth stay) were not excluded considering that only few
cases were expected and that transmission from the community (mother, siblings, family)
could not be ruled out.

140

141 Variable and categorical construction

- 142 A term delivery was defined as a baby born > 37 weeks of gestation (WG) measured in weeks
- 143 of amenorrhoea (WA). Moderate and very preterm deliveries were defined as a baby born \geq

144 32 WG and \leq 37 WG and a baby born \Box 32 WG, respectively.

145 Birth weight was categorised as either low or high when the value was outside 2 standard

146 deviations of the weight cohort distribution per WG. Month of birth was categorised into four

147 groups with increased incidence of RSVh during the first 6 months of life.

- 148 The choice to aggregate these two variables was made to match the categories used in 149 guidelines and clinical practice and to further facilitate the implementation of the.²⁵
- 150

151 **Cohort construction**

152 Overall, 45 648 infants were included in the study (2014 to 2018) from a catchment area of 1,370,678 inhabitants using public hospital registry data from the HCL (Figure 1).²⁶ To ensure 153 154 the stability of the score, the population studied was divided into three cohorts. The validating 155 cohort was defined as the 2018 birth cohort (n=8 709 infants born between January 2018 and 156 December 2018). The remaining cohort (2014 to 2017) was then randomly divided, with 157 equal-sized month of birth proportion, into a training cohort (70% of the remaining cohort, n=158 25 858) and a testing cohort (30% of the remaining cohort, n=11 081). The validating cohort was exposed to the 2018/2019 RSV season which was similar to the previous epidemics²⁷ 159 160 (Table 1).

162 Identification of predictors of interest and predictive score generation

To identify potential independent maternal RSVh predictors, all variables of the training cohort were entered into a multivariate backwards stepwise logistic regression model to remove predictors that did not significantly improve the fit of the logistic regression model (based on a p-value of 0•10). The odds ratio (OR) values obtained from the final model were rounded to the nearest integer and used to determine the score. The model was adjusted with the year of birth and the hospital of birth (Table 2).

169

170 Estimation of the model's performance and variance

To evaluate the optimism-corrected performance values, the real-life model's performance was quantified using the area under the receiver operating characteristic curve (AUROC) (with 95% confidence interval) and the Brier score in the testing and validating cohorts. A kfold (with k=4) cross validation approach was used to estimate the model's variance on the training cohort. The distribution of month of birth was preserved in the split training sets obtained using the k-fold cross validation. The validating cohort corresponds to a new set of infants exposed to a new RSV epidemic and was used as an external control.

In the absence of any similar predictive model but based on references from research on other medical predictive models, and given the potential cost-effectiveness of the preventive program, an AUROCC ≥ 0.70 was considered as evidence for good discrimination.^{28,29} A test was considered significant when p value was lower than 0.05.

182

183 Determining the cut-off values of the two-level preventive program

The optimal cut-off value for the first level of intervention (NPI alone) was defined *a priori* with minimal sensitivity and specificity values of 80 % and 20%, respectively. This cut-off assumed a lower cost and effectiveness for NPI compared to PI. However, an NPI preventive program may not be maintained all year-round if the perceived risk is too low. This

assumption was informed based on the results showing that the application of NPI measures

189 by French parents decreased over time during the COVID-19 crisis (CoviPrev survey).³⁰

190 The optimal cut-off value for the second level of intervention (NPI and PI) was defined *a* 191 *priori* with a minimal specificity value of 80%. This cut-off assumed a higher cost and 192 effectiveness for PI that would be then more suitable for a timely seasonal administration than 193 a year-round administration.³¹

194

195 Statistical analyses

196 Statistical analyses were performed using R software version 4.1.0 with the following 197 packages (ggplot2; reshape2; doBy; caret; scoring, pROC). The caret library was used for 198 data splitting. For the comparison of cohorts, p values were derived using the chi-squared test 199 for qualitative variables and the Student's t-test or ANOVA tests for quantitative variables.

200

201 Ethics

202 Parents of infants for whom hospitalisation data were used were informed of the study (aim of 203 the study, use of anonymised data, right to refuse participation) by postal mail. After this first 204 contact, data were anonymised. Parents of infants for whom hospitalisation data were used 205 were informed of the study (aim of the study, use of anonymised data, right to refuse 206 participation) by postal mail. After this first contact, data were anonymised. Authorisation 207 from Scientific and Ethical Committee of Hospices Civils de Lyon (Comité Scientifique et 208 Éthique des Hospices Civils de LYON CSE-HCL – IRB 00013204; Pr Cyrille Confavreux) 209 was obtained on 28/09/2021.

210

211 Role of the funding source

There was no funding source for this study. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

214

215

216 **Results**

217 Characteristics of the training, testing, and validating cohorts

218 Several patients were missing data for gestational age and were excluded (572/46 220). The 219 population studied comprised 45 648 infants, 50•7% (23 140) were boys, 16•1% (7 354) were 220 born preterm (\leq 37 WG), 5•8% (2 641) from multiple births, 20•8% (9 497) were born by 221 caesarean section, and 43.7% (19 933) from multiparous mothers. The median (Interquartile 222 Range [IQR]) birth weight was 3 207 [2 920 -3 580] g. Among them, 616 were hospitalised in 223 their first 6 months of life with a laboratory-confirmed RSV infection, 53.7% (331) were 224 boys, 22•8% (140) were born preterm (\leq 37 WG), 7•3% (45) from multiple births, and 73•4% 225 (452) from multiparous mothers (Table 1). Among all cases, 0.8% (5) were suspected to be 226 nosocomial. The characteristics of the testing and training cohorts did not significantly differ. 227 The validating cohort did not significantly differ in terms of mean WG and birth weight when 228 compared to the testing and training cohorts. Significant differences in the frequencies of 229 month of birth, parity, gestation type, and childbirth type were observed between the 230 validating cohort and the testing and training cohorts (Table 1).

231

232 Month of birth categorisation in the population studied

233 Month of birth was categorised into four groups with increased incidence of RSVh during the 234 first 6 months of life. In the population studied 95•1% (586/616) of the cases were detected 235 from November to February with a peak during December (Figure 2). Mean (\pm Standard 236 Deviation SD) age at the time of hospitalisation was 2•1 (\pm 1•4) months.

Incidence was 13•5 infants hospitalised in the first 6 months of life per 1000 infants (95%
Confidence Interval (CI) [12•0;15•0]). The incidence of RSVh in the first 6 months of life
was higher for those born just before the seasonal epidemic, from October to November (41•3

cases per 1000 infants (95% CI [37•0;46•0]) compared to those born in September and
December (23•0 cases per 1000 infants (95% CI [20•0;27•0]), as well as to those born in
January and June to August (7•53 cases per 1000 infants (95% CI [6•0;9•0]), and those born
February to May (0•81 cases per 1000 infants (95% CI [0•0;1•0]; Figure 2).
In the model analysis, the month of birth was aggregated into these four groups of respective

increased RSVh incidence. The choice to aggregate this variable was done to facilitate the implementation of the score in the patient and healthcare community in the context of pregnancy.

248

249 Maternal predictors of interest associated with increased risk of RSVh (training cohort)

250 The multivariate logistic regression analysis in the training cohort retrieved three variables 251 significantly associated with hospitalisation: month of birth, gestational age, and parity. 252 Considering the month of birth, being born during October and November was associated 253 with the highest risk of RSVh (OR 46•35, 95% CI [24•40;102•73], p <0•001). Considering 254 the gestational age, being born \Box 32 WG was associated with a higher risk of RSVh (OR 255 3•26, 95% CI [1•80;5•52], p <0•001). Considering parity, multiparity was associated with a higher risk of RSVh (OR 3.89, 95% CI [3•07; 4•97], p <0•001; Table 2). These variables, 256 257 along with the year of birth and the hospital of birth, were retained in the final predictive 258 model and used for the score construction.

259

260 Performance of the RSVh predictive score in the testing and validating cohorts

261 The final score value ranged from 0 to 53. The mean (\pm SD) score was 16•98 (\pm 16•42) in the

testing cohort and $18 \cdot 41 (\pm 19 \cdot 64)$ in the validating cohort (external control).

263 The k-fold validation approach used in the training cohort to estimate the model's variance

found a mean AUROC value of 0•791 (95% CI [0•788; 0•793]) for the four split training

cohorts compared with a mean AUROC value of 0.821 (95% CI: [0.791; 0.850]) for the validating cohort. The overlap between the two confidence intervals indicates a low variance. The Hosmer-Lemehow chi-squared test used to assess the goodness of fit (p value <0.001) and the Brier score measured (value = 0.0135) in the validating cohort both indicated a good performance of the predictive model.

270

271 Identifying the target population for the two-level maternal-infant preventive program

The optimal cut-off values of the RSVh predictive score for the first and second levels of intervention were 14 and 28, respectively. The maternal population with an RSVh predictive score below the first cut-off value (14) of intervention was defined as a low-risk group (Table 3). It encompasses all the mothers giving birth during the months of February to May and the deliveries occurring during the months of January or June to August with no more than one risk factor (prematurity or multiparity).

The maternal population with an RSVh predictive score above the first cut-off value (> 14) and below the second cut-off value (< 28) of intervention was defined as a moderate-risk group. It encompasses the deliveries occurring during the months of January or June to August with prematurity and multiparity and the deliveries in September or December with only one other risk factor (prematurity or multiparity).

The maternal population with an RSVh predictive score above the second cut-off value (> 28) was defined as a high-risk group. It encompasses the deliveries in September or December with prematurity and multiparity and all deliveries in October or November (Table 3).

286 When applied to the validating cohort, the predictive score identified 53% of infants as low-

287 risk (incidence 1.72 cases /1000 infants), 32% of infants as moderate-risk (incidence

288 18•92/1000 infants), and 15% of infants as high-risk (incidence 46•28/1000 infants; Table 3).

289

290 **Discussion**

In the present study, an original but simple approach was used to identify the target population for a two-level preventive mother-infant intervention program based on maternal and newborn risk factors.

The clinical predictors identified herein were already described in previous reports.^{19–21} Month of birth is by far the strongest predictor of RSVh in the general birth cohort. This finding is consistent with numerous previous observations reporting that infants born before the RSV peak month have the highest RSVh admission rates.³³ Prematurity under 37 WG and multiparity were also previously associated with increased RSVh risk.^{34,35}

The present approach differs from other RSVh prediction models.^{19–22} The novelty herein is 299 300 the use of RSVh risk factors that can be identified early in the pregnancy (month of birth and 301 multiparity) or at the infant's birth (WG). It allows the inclusion of target mothers and then 302 infants in a prevention program tailored to the infant's risk of RSVh. The first level entails a 303 reinforced behaviour change program (BCP) to promote good hygiene practices (hand 304 hygiene, breastfeeding, avoiding exposure to smoke and persons with acute respiratory 305 illness) and education on bronchiolitis. The second level is a pharmaceutical prevention 306 program that will integrate future licensed preventive drug interventions. These BCP and PI 307 can be introduced early during pregnancy follow-up so that the different healthcare workers 308 involved in the pregnancy, childbirth, and postnatal periods can repeatedly promote them to 309 the target population.

A major strength of this study was that all the diagnoses were PCR-confirmed, with only minor missing values. Indeed, identifying cases based on diagnosis codes, such as admissions for bronchiolitis, is neither fully specific nor sensitive. On one hand, bronchiolitis can be caused by other respiratory viruses such as rhinoviruses, metapneumoviruses, and influenzaviruses.³⁶ On the other hand, RSV admissions could be related to disease codes other than bronchiolitis (sepsis, acute otitis). According to the hospital's local protocol, all infants below the age of 1 year old hospitalised with acute respiratory infection, are tested for RSV

during the RSV epidemic season.²⁴ A sensitivity analysis performed over one RSV season (2016/2017) showed that 83•4% of all hospitalisations for bronchiolitis were due to RSV (PCR-confirmed), while 11•5% were related to other viruses (5% did not have any sample tested)³⁷. The second major strength of this work is that a complete case analysis was performed, as there was only a small proportion of infants excluded for missing data. In addition, dividing the population studied into three cohorts allowed a robust estimation of the score's performance.

324 There are, however, some limitations to this work. First, the cost-effectiveness of the future 325 licensed preventive treatments remains to be determined. One consequence of the COVID-19 326 crisis may be a better integration and promotion of NPI in the prevention of viral respiratory 327 diseases. Although more costly, the future drugs in development will likely represent a more 328 efficient preventive approach if dedicated to high-risk infants. Therefore, this two-step 329 strategy is likely to be considered in the near future. Another limitation is that some known risk factors (exposure to smoke, parent's education level, mother's age)³⁸ were not present in 330 331 the database and therefore not tested in the model. Palivuzimab use was also not measured in 332 this study. According to the French guidelines, Palivuzimab is recommended for premature 333 babies born before 29 WG or born before 32 WG with risk factors. This did not represent 334 more than 2% of the present birth cohort. Given that extremely premature infants are a small 335 subgroup of the general population, and that extreme prematurity was still a higher risk factor 336 than preterm and term births, it was assumed that the general model was not significantly 337 affected by the use of Palivizumab.

Using a hospital birth cohort, the NOHAN strategy allowed to determine strong maternal and newborn predictors of RSVh risk. By using this strategy, future parents could be enrolled early during pregnancy follow-up in a health-related BCP. The pregnant women could then be proposed a vaccine boost, or neutralizing monoclonal antibodies could be administered to the newborns. As demonstrated herein, the thresholds for triggering each level of intervention can

343	be adjusted to the local epidemiology, the resources available, and the evolving evidence						
344	concerning the cost-efficiency of the future interventions. Stakeholders, healthcare						
345	professionals and policy makers, should acknowledge this opportunity when designing the						
346	future of RSV prevention programs.						
347							

349

350 Table 1. Demographic and clinical characteristics of the training, testing, and validating

351 **cohorts**.

	Training Cohort 2014-2017 N=25 858	Testing Cohort 2014-2017 N=11 081	p value	Validating Cohort 2018 N=8 709	p value
Gender, n (%)					
Male	13 159 (50•9)	5 631 (50•8)	0•90	4 350 (50•0)	0•30
Month of birth, n (%)					
January	2 196 (8•5)	959 (8•7)	0•36	771 (8•9)	<0•0001
February	1 935 (7•5)	841 (7•6)		664 (7•6)	
March	2 152 (8•3)	865 (7•8)		708 (8•1)	
April	2 036 (7•8)	900 (8•1)		753 (8•7)	
May	2 268 (8•8)	913 (8•2)		753 (8•7)	
June	2 155 (8•3)	934 (8•4)		814 (9•4)	
July	2 209 (8•5)	995 (9•0)		821 (9•4)	
August	2 201 (8•5)	922 (8•3)		822 (9•5)	
September	2 120 (8•2)	962 (8•7)		793 (9•1)	
October	2 252 (8•7)	933 (8•4)		633 (7•3)	
November	2 208 (8•5)	920 (8•3)		608 (7•0)	
December	2 126 (8•2)	937 (8•5)		569 (6•5)	
Weeks of gestation, n (%)					
Median (IQR**)	39 [38-40]	39 [38-40]	0•54	39 [38-40]	0•06
> 37 weeks	21 649 (83•7)	9 273 (83•7)	0•77	7 372 (84•6)	0•16
\geq 32 and \leq 37 weeks	3 633 (14•0)	1 573 (14•2)		1 173 (13•5)	
\Box 32 weeks	576 (2•2)	235 (2•1)		164 (1•9)	
Parity, n (%)					
Primiparity	14 759 (57•1)	6 258 (56•5)	0•28	4 698 (53•9)	<0•0001
Multiparity	11 099 (42•9)	4 823 (43•5)		4 011 (46•1)	
Gestation, n (%)					
Single gestation	24 322 (94•1)	10 427 (94•1)	0•89	8 258 (94•8)	0•03
Multiple gestation	1 536 (6•0)	654 (5•9)		451 (5•2)	
Childbirth type, n (%)					
Vaginal birth	20 224(78•2)	8 694(78•5)	0•60	7 233 (83•0)	<0•0001
Caesarean section	5 634 (21•8)	2 387 (21•5)		1 476 (17•0)	
Birth weight (grams), n (%)					
Median (IQR)	3 260 [2 920-3 585]	3 270 [2 920-3 590]	0•54	3 260 [2920-3580]	0•78
Low Z score	464 (1•8)	199 (1•8)	0•70	229 (2•6)	<0•0001
Normal Z score	24 631 (95•2)	10 573 (95•4)		8 336 (95•7)	
Macrosomic Z score	763 (3•0)	309 (2•8)		144 (1•7)	
Year of birth, n (%)					
2014	6 386 (24•7)	2 754 (24•9)	0•03	0 (0)	NA
2015	6 554 (25•3)	2 648 (24•9)		0 (0)	
2016	6 377 (24•7)	2 807 (25•3)		0 (0)	
2017	6 541 (25•3)	2 872 (25•9)		0 (0)	
2018	0 (0)	0 (0)		8 709 (100)	

353 Abbreviations: IQR, interquartile range, NA: Not appropriate for testing

355 Table 2• Multivariate analysis of the risk factors for RSV-associated hospitalisation

- 356 during the first 6 months of life and predictive variables
- 357

Variable	Multivariable analysis			Final Model			Score
variable	OR	[95% CI]	P value	OR	[95% CI]	P value	OR round up
Sex							
Female		Reference					
Male	1•08	[0•85; 1•30]	0•66				
Month of birth							
February to May		Reference			Reference		0
January, June to August	9•25	[4•75; 20•84]	<0•0001	9•23	[5•10; 23•97]	<0•0001	9
September, December	22•82	[11•78; 51•21]	<0•0001	22•7	[11•75; 51•07]	<0•0001	23
October, November	46•35	[24•40; 102•73]	<0•0001	46•3	[24•41;	<0•0001	46
Gestational age							
>37 weeks		Reference			Reference		0
\geq 32 and \leq 37 weeks	1•64	[1•21; 2•20]	0•00	1•71	[1•29; 2•24]	0•00	2
<32 weeks	3•26	[1•80; 5•52]	<0•0001	3•43	[1•93; 5•68]	<0•0001	3
Parity							
Primiparity		Reference			Reference		0
Multiparity	3•89	[3•07; 4•97]	<0•0001	3•88	[3•06; 4•95]	<0•0001	4
Gestation							
Simple gestation		Reference					
Multiple gestation	1•16	[0•77; 1•70]	0•45				
Birth weight (%)		- · · · ·					
Normal Z score		Reference					
Low Z score	1•37	[0•53; 2•87]	0•46				
Macrosomic Z score	1•42	[0•81; 2•30]	0•19				

358 Abbreviations: OR, Odds Ratio; CI, confidence interval; NS, non-significant•

360 Table 3: Characteristics of the low-, moderate-, and high-risk groups according to the

361 predictive model•

362

	Low Risk Group	Moderate Risk Group	High Risk Group
Risk Factors	Any delivery February to May and deliveries in January or June to August with only one other risk factor (prematurity or multiparity)	Deliveries in January or June to August with prematurity and multiparity, and deliveries in September or December with only one other risk factor (prematurity or multiparity)	Any delivery in October to November and deliveries in September or December with two risk factors (prematurity and multiparity)
Preventive Intervention	Standard	Non Pharmaceutical Intervention Education Program	Non Pharmaceutical Intervention Education Program And Pharmaceutical Intervention Maternal Vaccine (term), or Monoclonal antibody (term, preterm)
Population proportion*	53% (4 643/8 709)	32% (2 748/8 709)	15% (1 318/8 709)
Incidence RSVh /1000**	1•72/1000	18•92/1000	46•28/1000

363 *Calculated on the validating cohort. Incidence of infants hospitalised in the first 6 months of

364 life per 1000 infants

366 Figure 1: Flowchart of the study

367



368

Figure 2• Incidence of infants hospitalised during the first six months of life according to

371 month of birth and number of hospitalisations per month in the studied population•

372



373

374 Red line: Number of RSVh per month; Black column: Incidence of RSVh in the first 6

375 months of life per 1000 infants stratified according to month of birth.

376

378 Contributors

- 379 MJ, JSC, MB, CH contributed to the literature search, the figures and study design. MJ, JSC,
- 380 MB, CH, SCT, AFMD, DP YG, EJ, and BL contributed to data collection, MJ, JSC, MB have
- 381 verified the underlying data. All authors, contributed to the data interpretation, critically
- 382 reviewed the manuscript, and approved the final manuscript for submission.
- 383

384 **Declaration of interests**

- 385 We declare no competing interests.
- 386

387 Data Sharing

- 388 Aggregated data are available on reasonable request.
- 389

390 Acknowledgement

- 391 We acknowledge the contribution of the paediatric department, laboratory technical staff, the
- 392 BEHcl Team, and Véréna Landel (Direction de la Recherche en Santé, HCL Proof Reading
- 393 of the manuscript).
- 394

395 **References**

- 396 1 Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response.
 397 *Paediatr Respir Rev* 2004; **5 Suppl A**: S119-126.
- Hall CB, Weinberg GA, Iwane MK, *et al.* The burden of respiratory syncytial virus infection in young children. *N Engl J Med* 2009; 360: 588–98.
- Shi T, McAllister DA, O'Brien KL, *et al.* Global, regional, and national disease burden
 estimates of acute lower respiratory infections due to respiratory syncytial virus in young
 children in 2015: a systematic review and modelling study. *Lancet* 2017; **390**: 946–58.
- 403 4 Deshpande SA, Northern V. The clinical and health economic burden of respiratory
 404 syncytial virus disease among children under 2 years of age in a defined geographical area.
 405 *Arch Dis Child* 2003; 88: 1065–9.
- 406 5 Reeves RM, Hardelid P, Panagiotopoulos N, Minaji M, Warburton F, Pebody R. Burden of
 407 hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: A
 408 data linkage modelling study. *J Infect* 2019; **78**: 468–75.

- Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory
 syncytial virus (RSV) infection. *J Pediatr* 2003; **143**: S112-117.
- 411 7 Murray J, Bottle A, Sharland M, *et al.* Risk factors for hospital admission with RSV
 412 bronchiolitis in England: a population-based birth cohort study. *PLoS One* 2014; 9:
 413 e89186.
- Hardelid P, Verfuerden M, McMenamin J, Smyth RL, Gilbert R. The contribution of child,
 family and health service factors to respiratory syncytial virus (RSV) hospital admissions
 in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015. *Euro Surveill* 2019;
 24. DOI:10.2807/1560-7917.ES.2019.24.1.1800046.
- Bracht M, Basevitz D, Cranis M, Paulley R, Paes B. Strategies for reducing the risk of
 respiratory syncytial virus infection in infants and young children: a Canadian nurses'
 perspective. *Neonatal Netw* 2012; **31**: 357–68.
- 421 10Casalegno J-S, Ploin D, Cantais A, et al. Characteristics of the delayed respiratory
 422 syncytial virus epidemic, 2020/2021, Rhône Loire, France. Euro Surveill 2021; 26:
 423 2100630.
- 11Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of
 COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. *Proc Natl Acad Sci U S A* 2020; **117**: 30547–53.
- 12Meissner HC, Welliver RC, Chartrand SA, *et al.* Immunoprophylaxis with palivizumab, a
 humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory
 syncytial virus infection in high risk infants: a consensus opinion. *Pediatr Infect Dis J*1999; 18: 223–31.
- 431 13Madhi SA, Polack FP, Piedra PA, *et al.* Respiratory Syncytial Virus Vaccination during
 432 Pregnancy and Effects in Infants. *New England Journal of Medicine* 2020; **383**: 426–39.
- 433 14Griffin MP, Yuan Y, Takas T, *et al.* Single-Dose Nirsevimab for Prevention of RSV in
 434 Preterm Infants. *New England Journal of Medicine* 2020; **383**: 415–25.
- 435 15Cody Meissner H. Approaching the End of the Era of Uncontrolled Respiratory Syncytial
 436 Virus Disease. *J Infect Dis* 2021; 223: 737–9.
- 437 16Artin B, Pitzer VE, Weinberger DM. Assessment and optimization of respiratory syncytial
 438 virus prophylaxis in Connecticut, 1996-2013. *Sci Rep* 2021; **11**: 10684.
- 17 Mazur NI, Higgins D, Nunes MC, *et al.* The respiratory syncytial virus vaccine landscape:
 lessons from the graveyard and promising candidates. *Lancet Infect Dis* 2018; 18: e295–
 311.
- 18Kappen TH, Peelen LM. Prediction models: the right tool for the right problem. *Curr Opin Anaesthesiol* 2016; **29**: 717–26.
- 19Simões EAF, Carbonell-Estrany X, Fullarton JR, *et al.* A predictive model for respiratory
 syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of
 gestational age, based on data from the Spanish FLIP Study. *Respir Res* 2008; **9**: 78.

- 20Sampalis JS, Langley J, Carbonell-Estrany X, *et al.* Development and validation of a risk
 scoring tool to predict respiratory syncytial virus hospitalization in premature infants born
 at 33 through 35 completed weeks of gestation. *Med Decis Making* 2008; 28: 471–80.
- 21 Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus
 prophylaxis in premature infants born at 33-35 completed weeks' gestational age in
 Canada. *Curr Med Res Opin* 2009; 25: 1585–91.
- 22Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, Dutch RSV Neonatal
 Network. Prospective validation of a prognostic model for respiratory syncytial virus
 bronchiolitis in late preterm infants: a multicenter birth cohort study. *PLoS One* 2013; 8:
 e59161.
- 457 23 Houben ML, Bont L, Wilbrink B, *et al.* Clinical prediction rule for RSV bronchiolitis in
 458 healthy newborns: prognostic birth cohort study. *Pediatrics* 2011; **127**: 35–41.
- 24Kramer R, Duclos A, VRS study group in Lyon, Lina B, Casalegno J-S. Cost and burden of
 RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France. *Vaccine* 2018; **36**: 6591–3.
- 462 25Blencowe H, Cousens S, Oestergaard MZ, *et al.* National, regional, and worldwide 463 estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected 464 countries: a systematic analysis and implications. *Lancet* 2012; **379**: 2162–72.
- 26Évolution et structure de la population en 2015 Population en 2015 | Insee.
 https://www.insee.fr/fr/statistiques/3564100?sommaire=3561107 (accessed Feb 2, 2022).
- 27 Demont C, Petrica N, Bardoulat I, *et al.* Economic and disease burden of RSV-associated
 hospitalizations in young children in France, from 2010 through 2018. *BMC Infect Dis*2021; 21: 730.
- 28Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiveroperating characteristic analysis for diagnostic tests. *Prev Vet Med* 2000; **45**: 23–41.
- 472 29 Youden WJ. Index for rating diagnostic tests. *Cancer* 1950; **3**: 32–5.
- 473 30CoviPrev□: une enquête pour suivre l'évolution des comportements et de la santé mentale
 474 pendant l'épidémie de COVID-19. https://www.santepubliquefrance.fr/etudes-et475 enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante476 mentale-pendant-l-epidemie-de-covid-19 (accessed Feb 2, 2022).
- 31Liu D, Leung K, Jit M, Wu JT. Cost-effectiveness of strategies for preventing paediatric
 lower respiratory infections associated with respiratory syncytial virus in eight Chinese
 cities. *Vaccine* 2021; 39: 5490–8.
- 32Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors
 for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. *Am J Epidemiol* 1991; 133: 1135–51.
- 33Wang X, Li Y, Vazquez Fernandez L, *et al.* Respiratory Syncytial Virus-Associated
 Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries. *J Infect Dis* 2022; : jiab560.

- 34Rietveld E, Vergouwe Y, Steyerberg EW, *et al.* Hospitalization for respiratory syncytial
 virus infection in young children: development of a clinical prediction rule. *Pediatr Infect Dis J* 2006; 25: 201–7.
- 35Rossi GA, Medici MC, Arcangeletti MC, *et al.* Risk factors for severe RSV-induced lower
 respiratory tract infection over four consecutive epidemics. *Eur J Pediatr* 2007; **166**: 1267–
 72.
- 36Papadopoulos NG, Moustaki M, Tsolia M, *et al.* Association of rhinovirus infection with
 increased disease severity in acute bronchiolitis. *Am J Respir Crit Care Med* 2002; 165:
 1285–9.
- 495 37Biot B, Gillet Y, Casalegno J-S. DETERMINANTS DE LA GRAVITE DES 496 BRONCHIOLITES ANALYSE DE А VRS. DES FACTEURS RISQUE 497 SOCIODEMOGRAPHIQUES, VIROLOGIQUES ET ENVIRONNEMENTAUX SUR LA 498 SAISON 2016-17 А LYON (Frech). 2018; published online June 15. 499 DOI:10.13140/RG.2.2.19956.48004.
- 38Fitzpatrick T, McNally JD, Stukel TA, *et al.* Family and Child Risk Factors for Early-Life
 RSV Illness. *Pediatrics* 2021; **147**: e2020029090.

502